14th Aug 2015 11:00
14 August 2015
Source BioScience plc
("Source BioScience" or the "Company")
RESULT OF GENERAL MEETING
The Company announces that at its General Meeting held today, shareholders passed the Resolution to approve the acquisition of Select Pharma Laboratories Limited (the "Acquisition").
Voting on the Resolution was as follows:
Resolution | For | Against | Withheld |
To approve the acquisition of the entire issued share capital of Select Pharma Laboratories Ltd | 134,666,449 | 7,934 | 1,330 |
Accordingly, the Acquisition is now unconditional save for admission of the 31,383,749 new ordinary shares being issued in connection with the previously announced placing.
Expected timetable of principal events
Each of the dates in the table below is indicative only and may be subject to change.
Expected date of admission of and commencement of dealings in the new ordinary shares on the London Stock Exchange | 17 August 2015 |
Expected date of completion of the acquisition | 17 August 2015 |
The times and dates set out in the expected timetable of principal events above may be adjusted by Source BioScience, in consultation with N+1 Singer, in which event details of the new times and dates will be notified to the UK Listing Authority and the London Stock Exchange and will be announced via a Regulatory Information Service.
- ENDS -
For further information, please contact:
Source BioScience plc
Dr Nick Ash, CEO
Tel: +44 (0) 115 973 9010
www.sourcebioscience.com
N+1 Singer (Financial Advisor, Sponsor and Broker)
Aubrey Powell/James White
Tel: +44 (0)207 496 3000
www.n1singer.com
About Source BioScience
Source BioScience plc (LSE: SBS) is a trusted provider of state of the art laboratory services and products to the healthcare and clinical, life and applied sciences and biopharma industries. It is an international business operating nine state of the art facilities in five countries and with customers in over 90 countries worldwide. The Group offers a complementary portfolio of laboratory services and products that share common technologies, laboratory processes, infrastructure and expertise. These include clinical diagnostics, genomics, proteomics, drug discovery and development research as well as controlled environment storage and testing services for a diverse range of markets. These services and products are provided to a large and diverse customer base including the top 50 pharmaceutical companies, leading universities and research institutes worldwide, the UK NHS and other healthcare providers. The Group is listed on the Premium Main Market of the London Stock Exchange.
Related Shares:
SBS.L